Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 5, Pages 2372-2390Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b01287
Keywords
-
Categories
Funding
- Spanish Ministerio de Economia y Competitividad (MINECO) [SAF2016-78792-R, SAF2015-66275-C2-1, RTI2018-097189-B-C21, SAF2016-79774-R]
- Wings for Life International Foundation
- Red de Terapia Celular (TERCEL)
- Instituto de Salud Carlos III MINECO [PI16/01698]
- Regional Development Funds-European Union (ERdfEU) [PI16/01698]
- National Institutes of Health [NS084398]
- MINECO [RH7777]
Ask authors/readers for more resources
Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA(1)) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA(1) agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA(1) receptor agonist described so far (E-max = 118%, EC50 = 0.24 mu M, KD = 19.6 nM; inactive at autotaxin and LPA(2-6) receptors). This compound induces characteristic LPA(1)-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available